Skip to main content
Dx & Vx Co., Ltd. logo

Dx & Vx Co., Ltd. — Investor Relations & Filings

Ticker · 180400 ISIN · KR7180400004 KO Manufacturing
Open in API
Filings indexed 474 across all filing types
Latest filing 2025-02-18 Director's Dealing
Country KR South Korea
Listing KO 180400

About Dx & Vx Co., Ltd.

https://www.dxvx.com/

Dx & Vx Co., Ltd. is a bio-healthcare company specializing in diagnostics and vaccine development. Its diagnostics division offers molecular diagnostic solutions, genomics and bioinformatics services, and customized companion diagnostics (CDx), leveraging an AI-based genome analysis platform. The company's therapeutic pipeline is centered on an innovative mRNA vaccine platform designed for long-term storage at room temperature. Key development areas include vaccines for infectious diseases, immuno-therapeutic cancer vaccines, oral treatments for obesity, and therapies for eye conditions. Additionally, Dx & Vx provides contract development, manufacturing, and sales organization (CDMO/CSO) services and commercializes microbiome-based products and health supplements.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/KRX). This is a standard regulatory filing used to disclose insider trading or changes in share ownership by company directors or major shareholders. In the provided taxonomy, this corresponds to 'Director's Dealing' (DIRS).
2025-02-18 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a standard disclosure for insider trading or changes in share ownership by company directors/executives, which corresponds to the 'Director's Dealing' category.
2025-02-18 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details a transaction (장내매수 - open market purchase) of shares by an executive (이수원, Vice President) of the company DXVX. This is a standard regulatory filing for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2025-02-18 Korean
주권매매거래정지 (관리종목지정우려)
Delisting Announcement Classification · 100% confidence The document is a short, official notice regarding the suspension of stock trading ('주권매매거래정지') for the company 'DXVX' due to concerns about being designated as an administrative stock ('관리종목지정우려'). It cites specific regulatory rules (KOSDAQ market disclosure regulations) and provides the duration and reason for the suspension. Since this is a regulatory announcement regarding market status and does not fit into specific categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2025-02-13 Korean
내부결산시점관리종목지정ㆍ형식적상장폐지ㆍ상장적격성실질심사사유발생
Delisting Announcement Classification · 100% confidence The document is a regulatory filing from a Korean company (DXVX) announcing the occurrence of grounds for administrative designation, potential delisting, and substantive review of listing eligibility due to financial losses identified during internal closing. It provides financial data, capital impairment ratios, and loss ratios, which are typical of a regulatory disclosure regarding financial health and listing status. Since it does not fit into specific categories like 'Annual Report' (10-K) or 'Earnings Release' (ER) but is a formal regulatory notification, it is classified as a Regulatory Filing (RNS).
2025-02-13 Korean
[기재정정]주요사항보고서(회사합병결정)
M&A Activity Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed by DXVX regarding the cancellation and withdrawal of a previously announced merger with Avixgen. It details the reasons for the termination of the merger agreement, specifically citing shareholder opposition and potential exercise of appraisal rights. Since this document pertains to the cancellation of a merger/takeover bid, it falls under the M&A Activity (TAR) category.
2025-01-09 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.